Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Celgene Starts the Year With a Bang

By Brian Orelli, PhD - May 14, 2018 at 2:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A solid first quarter and some acquisitions to boot.

Celgene ( CELG ) started the year off with a solid first quarter, leading management to raise its 2018 guidance already.

Celgene results: The raw numbers


Q1 2018

Q1 2017

Year-Over-Year Change


$3.54 billion

$2.96 billion


Income from operations

$218 million

$1,113 million


Earnings per share (EPS)




Adjusted EPS




Data source: Celgene.

What happened with Celgene this quarter?

  • The GAAP income and earnings numbers were wonky with acquisitions affecting the operating income and the new accounting standards resulting in a large gain that made almost all of it back at the EPS line. Long story short, adjusted EPS are definitely the best way to compare earnings year over year.
  • About three-quarters of the revenue growth is coming from volume increases -- as opposed to price increases -- which is good news with all the political talk of pricing pressure on drugs.
  • Sales of Revlimid were up 19% year over year, with sales in the U.S. benefiting from increased use in non-stem cell transplant and post-stem cell transplant maintenance therapy. Outside the U.S., sales are coming from frontline therapy and non-stem cell transplant patients, as well as some use of the drug in triplet combinations.
  • Pomalyst, which goes by Imnovid in some countries, had great growth in the U.S. with sales up 39%, but elsewhere sales were only up 3% because of price concessions in other countries where the blood cancer drug has plenty of competition.
  • Otezla continues its solid launch, with sales up 46% year over year. International sales drove the overall growth, with overseas sales up 79% year over year, but the U.S. is still going strong with growth of 39% year over year.
  • Even Abraxane, which has been a laggard, had a solid quarter with sales up 11% year over year.
  • During the quarter, Celgene closed on its acquisition of CAR T expert, Juno Therapeutics. It also picked up a JAK2 inhibitor, fedratinib, which is ready to be submitted to the Food and Drug Administration later this year.
  • After receiving a refuse to file letter for ozanimod to treat relapsing multiple sclerosis and talking with the FDA, Celgene needs to do more work to characterize a metabolite -- a compounds the patient's body breaks the drug down into -- which will delay the resubmission of the marketing application to the first quarter of next year.
Doctor talking to patient at a table

Image source: Getty Images.

What management had to say

While the ozanimod delay is disappointing, Celgene Chairman and CEO Mark Alles pointed out the acquisition of Juno, which came with JCAR017 among many other drugs, and fedratinib will make up for the pain. "Just the expected launched of fedratinib and JCAR017 in 2019 will enable us to absorb the financial impact cause by the delay in the expected launch of Ozanimod," he said.

Those companies aren't the only ones that CFO Peter Kellogg sees as a good investment, "In Q1, we purchased $2.7 billion of shares, bringing our total share repurchases over the last two quarters to $5.7 billion, reflecting our belief that the recent share price pressure presents a compelling investment opportunity."

Looking forward

After a strong first quarter, management raised its revenue guidance to approximately $14.8 billion, which was the high end of the previously forecast range. Guidance for the adjusted earnings line went down to $8.45 per share, from a previous guidance of $8.70 to $8.90, but that was entirely due to the increased spending on Juno's pipeline. Without the dilution from Juno, adjusted EPS would be $8.95 per share, higher than the previous guidance.

Management also reaffirmed its 2020 outlook for revenue of $19 billion to $20 billion and adjusted diluted EPS of greater than $12.50.

More immediately, investors will get to see a lot of data at the American Society for Clinical Oncology meeting next month, including results of the phase 3 Optimismm trial testing Pomalyst in combination with bortezomib and dexamethasone in multiple myeloma and the phase 3 Relevance trial comparing Revlimid and rituximab to rituximab plus chemotherapy in patients with follicular lymphoma. Data from both its new JCAR017 and older BB2121 CAR T therapies will be presented as will data from a trial testing Abraxane plus atezolizumab.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celgene Corporation Stock Quote
Celgene Corporation

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/05/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.